Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas

Apoptosis

Volumn 12, Issue 9, 2007, Pages 1645-1657

  Heikaus, Sebastian ^a   Casliskan, Ercan ^a   Mahotka, Csaba ^a   Gabbert, Helmut Erich ^a   Ramp, Uwe ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Apoptosis; cDNA array; Renal cell carcinoma; Topotecan; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RECOMBINANT CYTOKINE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TOPOTECAN; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA DAMAGE; DNA MICROARRAY; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; UPREGULATION;

APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOPOTECAN;

EID: 34547137144     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-007-0064-x     Document Type: Article

References (63)

1. Mulders P, Figlin R, deKernion JB et al (1997) Renal cell carcinoma: recent progress and future directions. Cancer Res 57:5189-5195
2. Steinbach F, Stockle M, Muller SC et al (1992) Conservative surgery of renal cell tumors in 140 patients: 21 years of experience. J Urol 148:24-29
3. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21:485-495
4. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375
5. Dejosez M, Ramp U, Mahotka C et al (2000) Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ 7:1127-1136
6. Ramp U, Mahotka C, Kalinski T, Ebel E, Gabbert HE, Gerharz CD (2001) Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types. Anticancer Res 21:3509-3517
7. Ramp U, Caliskan E, Mahotka C et al (2003) Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Br J Cancer 88:1800-1807
8. Kim R, Emi M, Tanabe K (2005) Caspase-dependent and -independent cell death pathways after DNA damage. Oncol Rep 14:595-599
9. Nachmias B, Ashhab Y, Ben-Yehuda D (2004) The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 14:231-243
10. Orrenius S (2004) Mitochondrial regulation of apoptotic cell death. Toxicol Lett 149:19-23
11. Baldini N (1997) Multidrug resistance-a multiplex phenomenon. Nat Med 3:378-380
12. Hetts SW (1998) To die or not to die: an overview of apoptosis and its role in disease. JAMA 279:300-307
13. Gerharz CD, Ramp U, Dejosez M et al (1999) Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab Invest 79:1521-1534
14. Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
15. Bodmer JL, Holler N, Reynard S et al (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2:241-243
16. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611-620
17. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818
18. Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501
19. Schendel SL, Azimov R, Pawlowski K, Godzik A, Kagan BL, Reed JC (1999) Ion channel activity of the BH3 only Bcl-2 family member, BID. J Biol Chem 274:21932-21936
20. Degli-Esposti MA, Smolak PJ, Walczak H et al (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186:1165-1170
21. Pan G, Ni J, Yu G, Wei YF, Dixit VM (1998) TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 424:41-45
22. Pai SI, Wu GS, Ozoren N et al (1998) Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58:3513-3518
23. Ozoren N, Fisher MJ, Kim K et al (2000) Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int J Oncol 16: 917-925
24. Roth W, Reed JC (2004) FLIP protein and TRAIL-induced apoptosis. Vitam Horm 67:189-206
25. Gerharz CD, Moll R, Storkel S, Ramp U, Thoenes W, Gabbert HE (1993) Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro. Am J Pathol 142:851-859
26. Gerharz CD, Ramp U, Olert J et al (1994) Cytomorphological, cytogenetic, and molecular biological characterization of four new human renal carcinoma cell lines of the clear cell type. Virchows Arch 424:403-409
27. Hollander MC, Alamo I, Jackman J, Wang MG, McBride OW, Fornace AJ Jr. (1993) Analysis of the mammalian gadd45 gene and its response to DNA damage. J Biol Chem 268:24385-24393
28. Johnson M, Dimitrov D, Vojta PJ et al (1994) Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 11:59-64
29. Pediconi N, Ianari A, Costanzo A et al (2003) Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 5:552-558
30. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468
31. Wu GS, Burns TF, McDonald ER 3rd et al (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17:141-143
32. Lin WC, Lin FT, Nevins JR (2001) Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15:1833-1844
33. Helin K, Harlow E, Fattaey A (1993) Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 13:6501-6508
34. Yamasaki L (2003) Role of the RB tumor suppressor in cancer. Cancer Treat Res 115:209-239
35. Hitchens MR, Robbins PD (2003) The role of the transcription factor DP in apoptosis. Apoptosis 8:461-468
36. Stanelle J, Stiewe T, Theseling CC, Peter M, Putzer BM (2002) Gene expression changes in response to E2F1 activation. Nucleic Acids Res 30:1859-1867
37. Zindy F, Eischen CM, Randle DH et al (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424-2433
38. Derijard B, Hibi M, Wu ICH et al (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037
39. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103:239-252
40. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604
41. Stevens C, Smith L, La Thangue NB (2003) Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5:401-409
42. Wu L, Timmers C, Maiti B et al (2001) The E2F1-3 transcription factors are essential for cellular proliferation. Nature 414:457-462
43. Wu X, Levine AJ (1994) p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91:3602-3606
44. Qin XQ, Livingston DM, Kaelin WG Jr, Adams PD (1994) Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 91:10918-10922
45. Shan B, Lee WH (1994) Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 14:8166-8173
46. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR (1995) E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 69:2491-2500
47. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR (1997) Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 94:7245-7250
48. Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR (1998) E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 9:113-118
49. Lindstrom MS, Wiman KG (2003) Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts. Oncogene 22:4993-5005
50. Robertson KD, Jones PA (1998) The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 18:6457-6473
51. Agami R, Bernards R (2000) Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 102:55-66
52. Maeda T, Hanna AN, Sim AB, Chua PP, Chong MT, Tron VA (2002) GADD45 regulates G2/M arrest, DNA repair, and cell death in keratinocytes following ultraviolet exposure. J Invest Dermatol 119:22-26
53. van Delft MF, Huang DC (2006) How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 16:203-213
54. Wrzesien-Kus A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T (2004) The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 9:705-715
55. Tanaka H, Matsumura I, Ezoe S et al (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 9:1017-1029
56. Lee MW, Park SC, Yang YG et al (2002) The involvement of reactive oxygen species (ROS) and p38 mitogen-activated protein (MAP) kinase in TRAIL/Apo2L-induced apoptosis. FEBS Lett 512:313-318
57. Danks MK, Pawlik CA, Whipple DO, Wolverton JS (1997) Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure. Clin Cancer Res 3:1731-1738
58. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189-1192
59. Khanna R, Morton CL, Danks MK, Potter PM (2000) Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 60:4725-4728
60. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044
61. Warburton HE, Brady M, Vlatkovic N, Linehan WM, Parsons K, Boyd MT (2005) p53 regulation and function in renal cell carcinoma. Cancer Res 65:6498-6503
62. Coutts AS, La Thangue NB (2005) The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun 331:778-785
63. Tsurutani J, Nitta T, Hirashima T et al (2002) Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer 35:299-304